Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Diethylstilbestrol (DES) is a synthetic, nonsteroidal estrogen that was historically prescribed for a variety of indications, including the prevention of miscarriage and premature labor in pregnant women, treatment of menopausal symptoms, and as therapy for breast and prostate cancer. It acts as an agonist at estrogen receptor. DES was also used as a growth promoter in animals. Its use declined after it was found to be ineffective for pregnancy support and linked to increased risks of clear cell adenocarcinoma and other adverse reproductive outcomes in those exposed prenatally. Today, its use is rare but may still occur in certain hormone-related cancers such as advanced prostate or breast cancer[1][2][3][4][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on diethylstilbestrol.